B-Tripla and a Bluey on Bondi Beach
By Bob Frascino, M.D.
April 7, 2011
BASD: Atripla, B-tripla, that's funny mate. So is B-tripla B-better than Atripla?
Dr. Bob: Well, it depends on how you define better. The head-to-head comparisons of the two "tripla" triples (single-tablet, once-daily formulations of the three antiretrovirals) are still ongoing. The only difference between these two regimens is rilpivirine substitutes for Sustiva. Both are co-formulated in combination with tenofovir and emtricitabine.
There have been two phase 3 studies (ECHO and THRIVE) comparing Sustiva (efavirenz) and rilpivirine. The data show rilpivirine is non-inferior (that's science-babble that means the study drug is no worse nor better than the drug it's being tested against). The good news is that rilpivirine was better tolerated than Sustiva. It also didn't raise cholesterol and triglycerides like Sustiva can. The not-so-good news is that Atripla performed better in folks with high viral loads (over 100,000) and that there was more virologic failure and resistance in the rilpivirine group. Another potentially worrisome finding was that rilpivirine resistance caused cross-resistance to Intelence, which hasn't been seen with Atripla.
BASD: Sustiva totally mind-warped me. It was like there were a few 'roos loose in my upper paddock. Really mate, I felt a few sausages short of a BBQ.
Dr. Bob: Actually I think a fair number of you Aussies already have a wicked case of the crazies, even without the Sustiva. How else can you explain the tendency of many Australian men of a certain age to wear knee-high socks with Bermuda shorts? And what about swimming in waters infested with sharks and stinging blue condoms?
BASD: You yanks are so hung up on sharks. Bloody oath mate, no one's been killed by a shark around here in ages ... I'd say it's been a couple of months at least.
Dr. Bob: "Couple of months?" Wow, and I'm supposed to find that news comforting?
BASD: But really mate, I couldn't take Sustiva. I was warned about vivid dreams, but didn't expect it would turn me into a resident of Zombieland.
Dr. Bob: I took Sustiva for a few weeks a number of years ago. I loved the vivid dreams. I remember waking Steve up just to tell him what I was dreaming about. The inhabitants of my Sustiva-induced dreamworld all seemed to be attired to appear in a Lady Gaga video, and I remember a particularly vivid three-way with Madonna and George Clooney. Although I can understand those who didn't live through the '70s (or at least sat through the current Broadway production of Priscilla Queen of the Desert) might be a bit put off by the sheer zaniness of the dream visions. For most folks on Sustiva the vivid dreams (or screaming nightmares) and other annoying side effects (difficulty concentrating, dizziness, mood changes, depression, etc.) tend to diminish after the first month or so. But there are other potential problems with Sustiva as well, including a load of drug-drug interactions, increases in cholesterol and triglycerides and the possibility of birth defects if taken by pregnant women.
BASD: So. the convenient once-daily dosing of Sustiva (or Atripla when it's combined with tenofovir and emtricitabine) is really counterbalanced by all the side effects and thingos?
Dr. Bob: Thingos?
BASD: Yeah, you know, wadjamacalits.
Dr. Bob: There you go again. Moving on. I should point out that since its approval in 2002, Sustiva (and Atripla) remains the preferred drug in all the published treatment guidelines. Its potency has never been bested in a clinical trial. Overall, compared to other antiretrovirals, it has an excellent long-term safety profile. Plus, it has a really, really long half-life.
BASD: You mean like Cher's?
Dr. Bob: Well, um, sorta, I guess.
BASD: So if Sustiva's so good, why even bother with rilpivirine?
Dr. Bob: Rilpivirine appears to have clear advantages over Sustiva in terms of side effects and should prove to be an attractive option for HIVers with low viral loads who are just starting treatment or for folks who can't tolerate Sustiva.
BASD: You ready to get wet again? How about you take my boogie-board and stay closer to shore. I'll try your surfboard on the bigger waves with the rest of the waxheads (surfers).
Dr. Bob: What about the blueies?
BASD: No worries mate. The water is fine. Just have a look at all the ankle biters (Aussie children) out there. Besides, blueies are nothing compared to box jellyfish, but they are more common up north.
Dr. Bob: I read about them in my travel books! They are the most poisonous creatures on the planet, aren't they?
BASD: Yeah, but if you stay out on dry land, you'll probably just get bitten by one of our giant poisonous spiders or venomous snakes.
Dr. Bob: I just read in my Truly Terrible Ways to Die While on Vacation Down Under book that out of the 10 most venomous and deadly snakes known to man, 11 of them reside here in Oz. And that they kill so fast that when bitten by one of these unspeakable slithering horrors, the victim's last words are "say, isn't that a sna ..."
I put the book down with trepidation and head for the water roller-coaster and the big blue floating potentially deadly condoms, which now seem as tame as baby kangaroos. But I ask you, dear reader, how much can a koala bear?
Want to get in touch with Dr. Bob? You can reach him through his "Ask the Experts" forum, by sending a message to the Robert James Frascino AIDS Foundation, or by leaving a comment for him below. (If it's a private message, or if it includes personal info such as your e-mail address or phone number, we won't post the comment, but we will send it along to him.)
Life, Love, Sex, HIV and Other Unscheduled Events
Bob Frascino, M.D., was President and Founder of The Robert James Frascino AIDS Foundation. He had been an outspoken, popular expert in TheBody.com's "Ask the Experts" forums on safe sex and fatigue/anemia since 2000. Once a Fellow of the American Academy of Allergy, Asthma, and Immunology, and the American Academy of Pediatrics, Dr. Frascino served as Associate Clinical Professor of Medicine, Division of Immunology, Rheumatology, and Allergy, at Stanford University Medical Center from 1983 until 2001. He was a member of the American Academy of HIV Medicine and had also been a distinguished member of the executive boards of numerous state and regional associations.
We're inexpressibly saddened to share the news that Dr. Frascino passed away unexpectedly on Saturday, Sept. 17, 2011. Click here to read more and to share your thoughts.
Subscribe to Dr. Bob's Blog:
October 19, 2011 - The Ultimate Unscheduled Event: A Blog Entry by Steven M. Natterstad, M.D.
September 23, 2011 - HIV Guidelines: Some Evolve; Some Don't. What's Up with That? Part Two -- A Blog Entry by Bob Frascino, M.D.
August 25, 2011 - HIV Guidelines: Some Evolve; Some Don't. What's Up With That? Part One: A Blog Entry by Bob Frascino, M.D.
July 27, 2011 - Three Decades of HIV/AIDS, Part Three: A Blog Entry by Bob Frascino, M.D.
June 30, 2011 - Three Decades of HIV/AIDS, Part Two: A Blog Entry by Bob Frascino, M.D.
Interviews With Dr. Bob:
Dr. Bob's "Ask the Experts" Forums on TheBody.com:
A Brief Disclaimer:
The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.